Prot#MB102-230: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus-Study Two

Project: Research project

Project Details

StatusFinished
Effective start/end date4/8/16 → 4/8/19

Funding

  • ICON Clinical Research, LLC (Prot#MB102-230 // Prot#MB102-230)
  • AstraZeneca AB (Prot#MB102-230 // Prot#MB102-230)